Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Joseph W. Chow"'
Autor:
Joseph W. Chow, Angela Wardman, David Wilson, Helen Broadhurst, Paul Newell, Katrina Yates, Karen Cheng
Publikováno v:
Drug Safety
Introduction Ceftazidime–avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam. Objectives The aim of this study was to evaluate the safety of ceftazidime–av
Autor:
Paurus Irani, Karen Cheng, Margaret Tawadrous, Joseph W. Chow, Yehuda Carmeli, John E. Mazuski, Antoni Torres, Florian M.E. Wagenlehner, David Bharucha, Gregory G. Stone, Dalia B. Wajsbrot
Publikováno v:
Infectious Diseases and Therapy
Introduction This exploratory analysis assessed efficacy and safety outcomes in patients with Gram-negative bacteremia treated with ceftazidime-avibactam or comparator across five phase 3, randomized, controlled, multi-center trials in adults with co
Autor:
Dianna Taylor, Joseph W. Chow, Gregory G. Stone, Patricia A. Bradford, Margaret Tawadrous, Zhangjing Chen, Mary Jane Cadatal
Publikováno v:
Antimicrob Agents Chemother
Nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), is increasingly associated with multidrug-resistant Gram-negative pathogens. This study describes the in vitro activity of ceftazidime-avibactam, ceftazidime, and relevant co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dd2f5c7232e8f0a2dd81f217eb705a5
https://europepmc.org/articles/PMC7179600/
https://europepmc.org/articles/PMC7179600/
Autor:
Joseph W. Chow, Gregory G. Stone, Angela Wardman, Jie Song, Helen Broadhurst, Paul Newell, Zhangjing Chen, Leanne B. Gasink, Katrina Yates
Publikováno v:
Journal of Antimicrobial Chemotherapy. 73:2519-2523
Objectives This analysis evaluated the clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa isolates pooled from the adult Phase III clinical trials in patients with complicated intra-abdominal infectio
Autor:
Nan Shan Zhong, Gregory G. Stone, Peter J. Laud, Dianna Taylor, Jean-François Timsit, Jan Pachl, Jie Song, Joseph W. Chow, Antoni Torres, Marin H. Kollef, Zhangjing Chen
Summary Background Nosocomial pneumonia is commonly associated with antimicrobial-resistant Gram-negative pathogens. We aimed to assess the efficacy and safety of ceftazidime-avibactam in patients with nosocomial pneumonia, including ventilator-assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6661bf4ffff3b0c3c0fd4244a022365c
https://eprints.whiterose.ac.uk/131236/1/THELANCETID-D-17-00793R2_SUBMITTED_02Oct17.pdf
https://eprints.whiterose.ac.uk/131236/1/THELANCETID-D-17-00793R2_SUBMITTED_02Oct17.pdf
Autor:
Michael S. Schwartz, Joseph W. Chow, Nicholas A. Kartsonis, Wendy Comisar, Sheng Bi, Angela Ngai, Julie A. Stone, Peng Sun, Susan Li, Gregory A. Winchell, Carole A. Sable
Publikováno v:
Clinical Pharmacology in Drug Development. 3:43-50
Caspofungin is an echinocandin antifungal agent administered once daily as an intravenous infusion. Relationships between caspofungin exposure and clinical efficacy and safety were investigated. End-of-infusion (CEOI ) and trough (C24 hours ) concent
Autor:
Jie Song, Min Ja Kim, Gregory G. Stone, Binh Giang Tran, Dung Anh Nguyen, Xinyu Qin, Peter J. Laud, Qian Chen, Joseph W. Chow, Lie Wang
Publikováno v:
International journal of antimicrobial agents. 49(5)
Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam
Publikováno v:
Antimicrobial Agents and Chemotherapy. 54:1590-1595
Directed evolution by random PCR mutagenesis of the gene for the aminoglycoside 2-IIa phosphotransferase generated R92H/D268N and N196D/D268N mutant enzymes, resulting in elevated levels of resistance to amikacin and isepamicin but not to other amino
Autor:
Maria Petrecz, Susan K. Bradshaw, Kim M. Strohmaier, Theoklis E. Zaoutis, Michael R. Bourque, Arlene Taylor, Johan Maertens, Angela L. Ngai, Andreas H. Groll, Nicholas A. Kartsonis, William J. Steinbach, Thomas Lehrnbecher, Hasan S. Jafri, Joseph W. Chow
Publikováno v:
Pediatric Infectious Disease Journal. 28:1132-1135
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever,
Autor:
Xavier Sáez-Llorens, Peng Sun, Susan K. Bradshaw, Janaki Raghavan, Mercedes Macias, Nicholas A. Kartsonis, Archana Chatterjee, Padmanabha Maiya, Joseph W. Chow, Marissa Fallon, Sheng Bi, Julie A. Stone, Juan G. Piñeros, Gloria Ruiz, Hasan S. Jafri, Kim M. Strohmaier
Publikováno v:
Antimicrobial Agents and Chemotherapy. 53:869-875
Candidainfections represent a major threat in neonatal intensive care units. This is the first prospective study to obtain caspofungin plasma levels and safety data for neonates and very young infants. Patients of n= 6) or subsequent multiple-dose (n